<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-21723" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Fibrate Medications</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Singh</surname>
            <given-names>Gauri</given-names>
          </name>
          <aff>Sharda University,Greater Noida</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Correa</surname>
            <given-names>Ricardo</given-names>
          </name>
          <aff>University of Arizona</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Gauri Singh declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ricardo Correa declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>1</day>
          <month>5</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-21723.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Fibrates are a class of drugs utilized in the management and treatment of dyslipidemia. This activity reviews the indications, action, and contraindications for fibrates as a valuable agent in managing serum cholesterol levels. This activity will highlight the mechanism of action, adverse event profile, and other key factors (e.g., monitoring, relevant interactions, etc.) pertinent for members of the healthcare team involved in the care of patients with atherogenic dyslipidemia and related conditions.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action and administration of fibrates.</p></list-item><list-item><p>Describe the adverse effects and contraindications of fibrates.</p></list-item><list-item><p>Review the potential toxicity of fibrates.</p></list-item><list-item><p>Outline interprofessional team strategies for improving care coordination and communication to advance fibrates and improve outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=21723&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=21723">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-21723.s2" sec-type="Indications">
        <title>Indications</title>
        <p>The fibrates are a type of amphipathic carboxylic acids belonging to the class of drugs&#x000a0;used to&#x000a0;lower serum cholesterol levels.&#x000a0;They are currently the most important class of drugs combating the worldwide epidemic of atherogenic dyslipidemia. Statins help reduce the levels of&#x000a0;low-density lipoprotein cholesterol (LDL) but do not&#x000a0;exert much of an effect on serum triglyceride or HDL levels, where the use of fibrates is required. Research shows that the effects of different fibrate medications, while essentially being the same, differ slightly&#x000a0;regarding their impact on glucose metabolism, insulin resistance, intermittent claudication, and microvascular effects of diabetes mellitus; this provides the option of tailoring therapy as per the needs of every patient.<xref ref-type="bibr" rid="article-21723.r1">[1]</xref>&#x000a0;The FDA approved indications of fibrates include :</p>
        <list list-type="bullet">
          <list-item>
            <p>For use as&#x000a0;an adjunct to dietary modifications (restricted in saturated fats and cholesterol) in adults with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson type IIa and IIb). Fibrates help&#x000a0;to reduce serum LDL, total cholesterol, triglycerides, apolipoprotein B (Apo-B) and increase high-density lipoprotein cholesterol (HDL).</p>
          </list-item>
          <list-item>
            <p>To be used, an adjunct to dietary modifications in adults with severe hypertriglyceridemia (Fredrickson type IV and V).</p>
          </list-item>
        </list>
        <p>A non-FDA-approved use of fibrates is primary biliary cholangitis.</p>
      </sec>
      <sec id="article-21723.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Fibrates work by a combination of the following mechanisms to cause their hypotriglyceridemic effects<xref ref-type="bibr" rid="article-21723.r2">[2]</xref>:</p>
        <list list-type="bullet">
          <list-item>
            <p>Reduce the availability of substrates to allow triglyceride synthesis in the liver.</p>
          </list-item>
          <list-item>
            <p>Reverse cholesterol movement and stimulate cellular fatty acid uptake and modulate low-density lipoprotein (LDL) receptor and ligand interaction. Fibrates promote receptor-mediated clearance of LDL after stimulating its secretion, causing this catabolism to occur at a 20% greater rate compared to an untreated patient. This action results in an overall decrease in very-low-density lipoproteins (VLDL).</p>
          </list-item>
          <list-item>
            <p>Small dense LDL, a fraction of LDL that produces the maximum peroxidation products, is reduced via the action of fibrates by activating lipoprotein lipase (LPL). Fibrates increase this LPL mediated lipolysis via activation of transcription factors for peroxisome proliferator-activated receptors (PPAR).<xref ref-type="bibr" rid="article-21723.r3">[3]</xref></p>
          </list-item>
        </list>
        <p>Fibrates also work to increase high-density lipoprotein (HDL) levels by upregulating the production of Apo-AI and apo-AII in the liver.</p>
      </sec>
      <sec id="article-21723.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Before starting fibrate therapy, patients should start on an adequate lipid-lowering diet. It should be used only as an adjunct to lipid-lowering diet and medication and not as a first-line mode of therapy.&#x000a0;</p>
        <p>Fibrates are administered orally, ideally as once a day tablets. According to the FDA, the dosing of fibrates in adults is as follows, adjusted for the patient profile :</p>
        <list list-type="bullet">
          <list-item>
            <p>Primary hypercholesterolemia or mixed dyslipidemia - Start with 120 mg daily.</p>
          </list-item>
          <list-item>
            <p>Severe hypertriglyceridemia - The dose ranges from 40 mg to 120 mg daily and is adjusted according to lipid levels.</p>
          </list-item>
          <list-item>
            <p>Renally impaired patients - Initiate with 40 mg per day. Conduct regular renal function tests and serum cholesterol levels and up-titrate the drug as required.</p>
          </list-item>
          <list-item>
            <p>Geriatric patients -&#x000a0;The dosing is per the renal function of the patient.</p>
          </list-item>
        </list>
        <p>The above regime is for fenofibrate, which is available as 40 mg and 120 mg tablets. The patient's response to it must be measured every 4 to 8 weeks, followed by adjusting the drug dosage.</p>
      </sec>
      <sec id="article-21723.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>&#x000a0;The following is a list of adverse effects of fibrates:</p>
        <list list-type="bullet">
          <list-item>
            <p>The most common adverse effects of this drug class include reporting of deranged AST, ALT levels, along with infrequent elevations in serum CPK (creatinine phosphokinase) levels during therapy.</p>
          </list-item>
          <list-item>
            <p>Most likely, due to the effect mediated by&#x000a0;PPAR-alpha,&#x000a0;fibrates&#x000a0;can reversibly increase serum creatinine and homocysteine levels. But clinical trials have failed to prove renal failure associated with this.</p>
          </list-item>
          <list-item>
            <p>Patients can present with leg cramps, abdominal pain, etc., as fibrates can cause a slightly increased risk (less than 1.0%)&#x000a0;of myopathy, cholelithiasis, and venous thrombosis.</p>
          </list-item>
          <list-item>
            <p>Fibrates generally should be avoided in combination with statins since they can inhibit statin metabolism, causing an increased risk of myopathy. Recommendations are to always to measure serum creatinine levels and renal function before using the two drugs simultaneously. Gemfibrozil has proved to be unsafe for this interaction, whereas clinicians can still use bezafibrate and fenofibrate.</p>
          </list-item>
          <list-item>
            <p>Discontinue fibrate therapy or reduce the fibrate dose if a clinically significant elevation of serum creatinine occurs in the patient, after excluding all possible causes&#x000a0;for the same.<xref ref-type="bibr" rid="article-21723.r4">[4]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-21723.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>The contra-indications to the use of fibrate therapy are:</p>
        <list list-type="bullet">
          <list-item>
            <p>Known hypersensitivity to the drug class.</p>
          </list-item>
          <list-item>
            <p>Active liver disease, as fibrates are shown to be hepatotoxic if pre-existing liver inflammatory states exist.<xref ref-type="bibr" rid="article-21723.r5">[5]</xref></p>
          </list-item>
          <list-item>
            <p>Active gall bladder disease as fibrates cause a PPAR-Alpha mediated downregulation in bile acid production, which, in turn, is responsible for an increased tendency to form gall stones.<xref ref-type="bibr" rid="article-21723.r6">[6]</xref></p>
          </list-item>
          <list-item>
            <p>Severe renal dysfunction, including patients receiving dialysis therapy.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-21723.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Fibrates are usually safe drugs that do not need routine monitoring except in the following cases:</p>
        <list list-type="bullet">
          <list-item>
            <p>Co-administration with statins increases the risk for myopathy. Monitor these patients for serum CPK levels, especially if they have diabetes, hypothyroidism, or renal failure.</p>
          </list-item>
          <list-item>
            <p>Monitor renal function tests in patients with pre-existing deranged renal function.</p>
          </list-item>
          <list-item>
            <p>Monitor serum transaminases since fibrates can sometimes elevate&#x000a0;these levels.</p>
          </list-item>
          <list-item>
            <p>Conduct gallbladder studies in patients with pre-existing gallbladder disease or if cholelithiasis is suspected.</p>
          </list-item>
          <list-item>
            <p>Monitor PT/INR levels at least thrice a week when co-administering with coumarin anti-coagulants to prevent bleeding complications as fibrates are known to potentiate the effects of the former.<xref ref-type="bibr" rid="article-21723.r7">[7]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-21723.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <list list-type="bullet">
          <list-item>
            <p>There is no known antidote to fibrate toxicity. If possible, eliminate any unabsorbed drug via emesis or gastric lavage, maintaining the necessary common precautions for airway protection.</p>
          </list-item>
          <list-item>
            <p>If a patient happens to overdose on fibrates, do not consider hemodialysis as fibrates are highly plasma protein-bound drugs.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-21723.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Managing appropriate drug use requires&#x000a0;free-flowing and efficient communication between&#x000a0;the entire interprofessional healthcare team, including clinicians, mid-level practitioners, nurses, and pharmacists. The same applies to the use of fibrates. Health professionals should bear in mind the adverse outcome of fibrates regarding liver function tests (LFTs) and ensure that there is regular testing, especially if the patient has pre-existing liver disease. Fibrates are also notorious for causing drug interactions, and health professionals should be thorough with the patient's medication history before prescribing them.&#x000a0;If a patient is already on statins, monitor carefully for the development of myopathies, evaluate clotting studies for those on anticoagulants, etc. Most importantly, it is the responsibility of healthcare providers to counsel the patients about the adverse effects of this drug and ensure they report any new or untoward symptoms(such as muscle cramps, abdominal pain, indigestion, etc.) after initiating the drug.</p>
        <p>An interprofessional team effort is necessary to accomplish the above. The clinician will make the decision to initiate fibrate therapy based on the case facts before them. Still, they would do well to include a pharmacist who can review the patient's current medications to check for possible drug interactions and verify appropriate dosing. The pharmacist can also assist in choosing a specific fibrate depending on the patient's particular parameters. Nursing should be aware of the signs of the most common interactions and adverse effects; they can check on patient compliance and monitor for adverse events, alerting the prescriber when appropriate. In this way, fibrate therapy can achieve the best possible result with minimal chance of encountering adverse effects. [Level 5]</p>
      </sec>
      <sec id="article-21723.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=21723&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=21723">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/21723/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=21723">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-21723.s11">
        <title>References</title>
        <ref id="article-21723.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tenenbaum</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fisman</surname>
                <given-names>EZ</given-names>
              </name>
            </person-group>
            <article-title>Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction.</article-title>
            <source>Cardiovasc Diabetol</source>
            <year>2012</year>
            <month>Oct</month>
            <day>11</day>
            <volume>11</volume>
            <fpage>125</fpage>
            <pub-id pub-id-type="pmid">23057687</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21723.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shepherd</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Mechanism of action of fibrates.</article-title>
            <source>Postgrad Med J</source>
            <year>1993</year>
            <volume>69 Suppl 1</volume>
            <fpage>S34</fpage>
            <page-range>S34-41</page-range>
            <pub-id pub-id-type="pmid">8497455</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21723.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Staels</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Dallongeville</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Auwerx</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Schoonjans</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Leitersdorf</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Fruchart</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>Mechanism of action of fibrates on lipid and lipoprotein metabolism.</article-title>
            <source>Circulation</source>
            <year>1998</year>
            <month>Nov</month>
            <day>10</day>
            <volume>98</volume>
            <issue>19</issue>
            <fpage>2088</fpage>
            <page-range>2088-93</page-range>
            <pub-id pub-id-type="pmid">9808609</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21723.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Davidson</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Armani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>McKenney</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Jacobson</surname>
                <given-names>TA</given-names>
              </name>
            </person-group>
            <article-title>Safety considerations with fibrate therapy.</article-title>
            <source>Am J Cardiol</source>
            <year>2007</year>
            <month>Mar</month>
            <day>19</day>
            <volume>99</volume>
            <issue>6A</issue>
            <fpage>3C</fpage>
            <page-range>3C-18C</page-range>
            <pub-id pub-id-type="pmid">17368275</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21723.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>&#x00160;kop</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Trnovsk&#x000e1;</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Oliyarnyk</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Markov&#x000e1;</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Mal&#x000ed;nsk&#x000e1;</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kazdov&#x000e1;</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Z&#x000ed;dek</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Landa</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Mlejnek</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>&#x00160;im&#x000e1;kov&#x000e1;</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>K&#x0016f;dela</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pravenec</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>&#x00160;ilhav&#x000fd;</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Hepatotoxic effects of fenofibrate in spontaneously hypertensive rats expressing human C-reactive protein.</article-title>
            <source>Physiol Res</source>
            <year>2016</year>
            <month>Dec</month>
            <day>13</day>
            <volume>65</volume>
            <issue>6</issue>
            <fpage>891</fpage>
            <page-range>891-899</page-range>
            <pub-id pub-id-type="pmid">27539098</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21723.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Post</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Duez</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Gervois</surname>
                <given-names>PP</given-names>
              </name>
              <name>
                <surname>Staels</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kuipers</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Princen</surname>
                <given-names>HM</given-names>
              </name>
            </person-group>
            <article-title>Fibrates suppress bile acid synthesis via peroxisome proliferator-activated receptor-alpha-mediated downregulation of cholesterol 7alpha-hydroxylase and sterol 27-hydroxylase expression.</article-title>
            <source>Arterioscler Thromb Vasc Biol</source>
            <year>2001</year>
            <month>Nov</month>
            <volume>21</volume>
            <issue>11</issue>
            <fpage>1840</fpage>
            <page-range>1840-5</page-range>
            <pub-id pub-id-type="pmid">11701475</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21723.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ascah</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Rock</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Wells</surname>
                <given-names>PS</given-names>
              </name>
            </person-group>
            <article-title>Interaction between fenofibrate and warfarin.</article-title>
            <source>Ann Pharmacother</source>
            <year>1998</year>
            <season>Jul-Aug</season>
            <volume>32</volume>
            <issue>7-8</issue>
            <fpage>765</fpage>
            <page-range>765-8</page-range>
            <pub-id pub-id-type="pmid">9681093</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
